Literature DB >> 26916892

Systemic Juvenile Idiopathic Arthritis: Diagnosis and Management.

Sathish Kumar1.   

Abstract

Systemic juvenile idiopathic arthritis (sJIA) is an inflammatory condition characterized by fever, lymphadenopathy, arthritis, rash and serositis. In sJIA, systemic inflammation has been associated with dysregulation of the innate immune system, suggesting that it is an autoinflammatory disorder. IL-1 and IL-6 play a major role in the pathogenesis of sJIA and treatment with IL-1 and IL-6 inhibitors has shown to be highly effective. Recent data suggests that early cytokine blockage might abrogate chronic, destructive, therapy resistant arthritis phase, reflecting a potential "window of opportunity" in the care of children with sJIA.

Entities:  

Keywords:  Interleukin-1 blockade; Systemic JIA; Treatment

Mesh:

Substances:

Year:  2016        PMID: 26916892     DOI: 10.1007/s12098-016-2060-z

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  35 in total

1.  Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders.

Authors:  S Sawhney; P Woo; K J Murray
Journal:  Arch Dis Child       Date:  2001-11       Impact factor: 3.791

Review 2.  Systemic onset juvenile rheumatoid arthritis.

Authors:  R Schneider; R M Laxer
Journal:  Baillieres Clin Rheumatol       Date:  1998-05

3.  On a Form of Chronic Joint Disease in Children.

Authors:  G F Still
Journal:  Med Chir Trans       Date:  1897

Review 4.  Systemic juvenile idiopathic arthritis.

Authors:  Alberto Martini
Journal:  Autoimmun Rev       Date:  2012-08-02       Impact factor: 9.754

5.  Other extraarticular manifestations of juvenile rheumatoid arthritis.

Authors:  J J Calabro
Journal:  Arthritis Rheum       Date:  1977-03

6.  Amyloidosis in juvenile chronic polyarthritis.

Authors:  T J Schnitzer; B M Ansell
Journal:  Arthritis Rheum       Date:  1977-03

Review 7.  2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications.

Authors:  Sarah Ringold; Pamela F Weiss; Timothy Beukelman; Esi Morgan Dewitt; Norman T Ilowite; Yukiko Kimura; Ronald M Laxer; Daniel J Lovell; Peter A Nigrovic; Angela Byun Robinson; Richard K Vehe
Journal:  Arthritis Care Res (Hoboken)       Date:  2013-10       Impact factor: 4.794

Review 8.  Advances in the pathogenesis and treatment of systemic juvenile idiopathic arthritis.

Authors:  Colleen K Correll; Bryce A Binstadt
Journal:  Pediatr Res       Date:  2013-11-08       Impact factor: 3.756

9.  Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial.

Authors:  Shumpei Yokota; Tomoyuki Imagawa; Masaaki Mori; Takako Miyamae; Yukoh Aihara; Shuji Takei; Naomi Iwata; Hiroaki Umebayashi; Takuji Murata; Mari Miyoshi; Minako Tomiita; Norihiro Nishimoto; Tadamitsu Kishimoto
Journal:  Lancet       Date:  2008-03-22       Impact factor: 79.321

10.  Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis.

Authors:  Nicolino Ruperto; Hermine I Brunner; Pierre Quartier; Tamás Constantin; Nico Wulffraat; Gerd Horneff; Riva Brik; Liza McCann; Ozgur Kasapcopur; Lidia Rutkowska-Sak; Rayfel Schneider; Yackov Berkun; Inmaculada Calvo; Muferet Erguven; Laurence Goffin; Michael Hofer; Tilmann Kallinich; Sheila K Oliveira; Yosef Uziel; Stefania Viola; Kiran Nistala; Carine Wouters; Rolando Cimaz; Manuel A Ferrandiz; Berit Flato; Maria Luz Gamir; Isabelle Kone-Paut; Alexei Grom; Bo Magnusson; Seza Ozen; Flavio Sztajnbok; Karine Lheritier; Ken Abrams; Dennis Kim; Alberto Martini; Daniel J Lovell
Journal:  N Engl J Med       Date:  2012-12-20       Impact factor: 91.245

View more
  3 in total

1.  Juvenile Idiopathic Arthritis.

Authors:  Kenan Barut; Amra Adrovic; Sezgin Şahin; Özgür Kasapçopur
Journal:  Balkan Med J       Date:  2017-04-05       Impact factor: 2.021

2.  Anakinra Drug Retention Rate and Predictive Factors of Long-Term Response in Systemic Juvenile Idiopathic Arthritis and Adult Onset Still Disease.

Authors:  Jurgen Sota; Donato Rigante; Piero Ruscitti; Antonella Insalaco; Paolo Sfriso; Salvatore de Vita; Rolando Cimaz; Giuseppe Lopalco; Giacomo Emmi; Francesco La Torre; Claudia Fabiani; Alma Nunzia Olivieri; Marco Cattalini; Daniele Cammelli; Romina Gallizzi; Maria Alessio; Raffaele Manna; Ombretta Viapiana; Micol Frassi; Manuela Pardeo; Armin Maier; Carlo Salvarani; Rosaria Talarico; Marta Mosca; Serena Colafrancesco; Roberta Priori; Maria Cristina Maggio; Carla Gaggiano; Salvatore Grosso; Fabrizio De Benedetti; Antonio Vitale; Roberto Giacomelli; Luca Cantarini
Journal:  Front Pharmacol       Date:  2019-08-23       Impact factor: 5.810

3.  Clinical features and outcomes of patients with hemophagocytic lymphohistiocytosis at onset of systemic autoinflammatory disorder and compare with Epstein-Barr virus (EBV)-related hemophagocytic lymphohistiocytosis.

Authors:  Yunze Zhao; Zhigang Li; Li Zhang; Hongyun Lian; Honghao Ma; Dong Wang; Xiaoxi Zhao; Qing Zhang; Tianyou Wang; Rui Zhang
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.